PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
A study investigating a high dose (0.4 mg/kg) of the bolus thrombolytic tenecteplase in the treatment of patients with moderate to severe acute ischemic stroke was stopped prematurely because of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results